百濟神州(06160.HK)將發布「百悅澤」重要研究數據
百濟神州(06160.HK)公布,將於第17屆國際惡性淋巴瘤會議上,發布旗下產品「百悅澤」(澤布替尼)的最新重要研究數據。
百濟神州血液學首席醫學官Mehrdad Mobasher表示,數據進一步印證公司對該藥物的信心,更新分析結果強化此前澤布替尼聯合奧妥珠單抗在2期ROSEWOOD試驗中所取得的結果。
公司早前宣布,歐洲藥品管理局(EMA)已受理澤布替尼聯合奧妥珠單抗,用於治療既往接受過至少兩線治療的成人復發╱難治性(R/R)濾泡性淋巴瘤(FL)的申請。他透露,全球其他市場的相關藥政申報工作也在進行中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.